Meeting
2024 ASCO Breakthrough
Validating process mining in pediatric oncology: Demonstrating protocol adherence and variability in neuroblastoma treatment.
Authors
Astrid van Barneveld
Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands
Astrid van Barneveld , Matthijs Berkhout , Max Van Noesel , Patrick Kemmeren , Lieve Tytgat
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics
Sub Track
Other Technology and Innovations
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 166)
DOI
10.1200/JCO.2024.42.23_suppl.166
Abstract #
166
Poster Bd #
F10
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Evaluation of palbociclib in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory neuroblastoma.
First Author: Theodore Willis Laetsch
Poster
2019 Breakthrough
Ned-170: A combination anti-cancer therapy targeting late stage, heavily pre-treated solid tumor malignancies.
First Author: Edward Graeme Garmey
Poster
2017 Cancer Survivorship Symposium
Long-term side effects of high-risk neuroblastoma survivors in a referral center in central Illinois.
First Author: Beth Speckhart
Poster
2016 ASCO Annual Meeting
Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study.
First Author: Milena Bruzzone